Positive outcomes for pancreatic vaccine

A recent study has shown that the "M. Keras-Vax" vaccine, developed by researchers at Johns Hopkins University, is safe and elicits a long-term immune response against the "Keras" genetic mutation responsible for pancreatic cancer. The trial involved 20 high-risk patients, and the vaccine successfully activated immune cells in 90% of them, with the response lasting up to two years. None of the participants developed pancreatic cancer after an average follow-up of 16.5 months. The results indicate that the vaccine represents an initial step toward preventing this disease, although the study has not yet proven its ability to definitively prevent cancer.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل